<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Trade</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Life sciences ‘sweet’ opportunity in US-China talks </title>
      <description>
        <![CDATA[Of all the issues that could be on the table at the talks between U.S. President Donald Trump and China President Xi Jinping, the life sciences sector is the “sweet spot” for collaboration between the two countries in a way that would benefit the world, Sen. Thom Tillis, R-N.C., said in a Brookings Institution webinar in advance of the two-day summit that starts May 14.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731365</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731365-life-sciences-sweet-opportunity-in-us-china-talks</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-and-US-flags.webp?t=1623269249" type="image/png" medium="image" fileSize="378844">
        <media:title type="plain">China and U.S. flags</media:title>
      </media:content>
    </item>
    <item>
      <title>Life sciences ‘sweet’ opportunity in US-China talks </title>
      <description>
        <![CDATA[Of all the issues that could be on the table at the talks between U.S. President Donald Trump and China President Xi Jinping, the life sciences sector is the “sweet spot” for collaboration between the two countries in a way that would benefit the world, Sen. Thom Tillis, R-N.C., said in a Brookings Institution webinar in advance of the two-day summit that starts May 14.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731060</guid>
      <pubDate>Wed, 13 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731060-life-sciences-sweet-opportunity-in-us-china-talks</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-and-US-flags.webp?t=1623269249" type="image/png" medium="image" fileSize="378844">
        <media:title type="plain">China and U.S. flags</media:title>
      </media:content>
    </item>
    <item>
      <title>Multiple appearances on Priority Watch List leading to action?</title>
      <description>
        <![CDATA[It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report was no exception.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731225</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731225-multiple-appearances-on-priority-watch-list-leading-to-action</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Magnifying-glass-on-wooden-table.webp?t=1721409551" type="image/jpeg" medium="image" fileSize="152426">
        <media:title type="plain">Magnifying glass on wooden table</media:title>
      </media:content>
    </item>
    <item>
      <title>Commerce gives Rx companies 30 days to submit US onshoring plans </title>
      <description>
        <![CDATA[Companies seeking a break in the soon-to-be-implemented U.S. Section 232 biopharma tariffs have 30 days to apply for a company-specific onshoring agreement with the Department of Commerce, according to the procedures the department laid out in a notice to be published in the May 13 <em>Federal Register</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731049</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731049-commerce-gives-rx-companies-30-days-to-submit-us-onshoring-plans</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-map-with-arrows-pointing-inward.webp?t=1754599645" type="image/jpeg" medium="image" fileSize="247248">
        <media:title type="plain">US map with arrows pointing inward</media:title>
      </media:content>
    </item>
    <item>
      <title>Multiple appearances on Priority Watch List leading to action?</title>
      <description>
        <![CDATA[It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report was no exception.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730867</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730867-multiple-appearances-on-priority-watch-list-leading-to-action</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Magnifying-glass-on-wooden-table.webp?t=1721409551" type="image/jpeg" medium="image" fileSize="152426">
        <media:title type="plain">Magnifying glass on wooden table</media:title>
      </media:content>
    </item>
    <item>
      <title>USTR calls out trade partners for Rx, med-tech pricing policies </title>
      <description>
        <![CDATA[For the first time in 13 years, the U.S. Trade Representative (USTR) singled out one of the U.S. trading partners as the worst of the worst when it named Vietnam as a Priority Foreign Country (PFC) in its newly released Special 301 Report.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730920</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730920-ustr-calls-out-trade-partners-for-rx-med-tech-pricing-policies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Map-of-Vietnam.webp?t=1777928544" type="image/jpeg" medium="image" fileSize="172581">
        <media:title type="plain">Map of Vietnam</media:title>
      </media:content>
    </item>
    <item>
      <title>White House looks to expand MFN pricing for $530B-plus in savings </title>
      <description>
        <![CDATA[Amid calls for transparency on the most-favored nation (MFN) pricing deals U.S. President Donald Trump has reached with 17 biopharma companies, the White House Council of Economic Advisers released a report May 5 detailing how the volunteer MFN policy works and touting the $530 billion-plus in savings it’s projected to deliver over the next 10 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730850</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730850-white-house-looks-to-expand-mfn-pricing-for-530b-plus-in-savings</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-pricing-illustration.webp?t=1598557470" type="image/png" medium="image" fileSize="365578">
        <media:title type="plain">Prescription drug bottle, pills shaped in $ sign</media:title>
      </media:content>
    </item>
    <item>
      <title>USTR calls out trade partners for Rx, med-tech pricing policies </title>
      <description>
        <![CDATA[For the first time in 13 years, the U.S. Trade Representative (USTR) singled out one of the U.S. trading partners as the worst of the worst when it named Vietnam as a Priority Foreign Country (PFC) in its newly released Special 301 Report.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730832</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730832-ustr-calls-out-trade-partners-for-rx-med-tech-pricing-policies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Map-of-Vietnam.webp?t=1777928544" type="image/jpeg" medium="image" fileSize="172581">
        <media:title type="plain">Map of Vietnam</media:title>
      </media:content>
    </item>
    <item>
      <title>Sector tariff now more than a threat – for some Rx companies</title>
      <description>
        <![CDATA[After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump finally delivered it. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730236</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730236-sector-tariff-now-more-than-a-threat-for-some-rx-companies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tariff-trade-illustration.webp?t=1746219221" type="image/jpeg" medium="image" fileSize="370006">
        <media:title type="plain">Digital globe illustrating pharma trade, tariffs</media:title>
      </media:content>
    </item>
    <item>
      <title>Sector tariff now more than a threat – for some Rx companies</title>
      <description>
        <![CDATA[After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump finally delivered it. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. However, depending on the drug, where it’s made and whether a manufacturer has reached onshoring and pricing agreements with the Department of Health and Human Services, the actual tariff could be as low as 0%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730116</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730116-sector-tariff-now-more-than-a-threat-for-some-rx-companies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tariff-trade-illustration.webp?t=1746219221" type="image/jpeg" medium="image" fileSize="370006">
        <media:title type="plain">Digital globe illustrating pharma trade, tariffs</media:title>
      </media:content>
    </item>
    <item>
      <title>US taking a closer look at China biotech subsidies </title>
      <description>
        <![CDATA[U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729320</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729320-us-taking-a-closer-look-at-china-biotech-subsidies</link>
    </item>
    <item>
      <title>US taking a closer look at China biotech subsidies </title>
      <description>
        <![CDATA[U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729247</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729247-us-taking-a-closer-look-at-china-biotech-subsidies</link>
    </item>
    <item>
      <title>Supreme Court ruling not a death knell for US tariffs </title>
      <description>
        <![CDATA[The ramifications of the U.S. Supreme Court’s decision Feb. 20 that shot down President Donald Trump’s reciprocal tariffs issued under the International Emergency Economic Powers Act are rippling across the world. And Trump’s immediate response to that ruling – a proclamation imposing a temporary 10% import duty on most goods brought into the country beginning Feb. 24 – isn’t helping.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729181</guid>
      <pubDate>Mon, 23 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729181-supreme-court-ruling-not-a-death-knell-for-us-tariffs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/US-tariff-illustration.webp?t=1771885827" type="image/jpeg" medium="image" fileSize="745064">
        <media:title type="plain">US flag, money, global currency symbols, tariff arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>VCs launch coalition to strengthen Europe life sciences investment</title>
      <description>
        <![CDATA[Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729083</guid>
      <pubDate>Fri, 13 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729083-vcs-launch-coalition-to-strengthen-europe-life-sciences-investment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.webp?t=1729025266" type="image/jpeg" medium="image" fileSize="220776">
        <media:title type="plain">Gold Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>VCs launch coalition to strengthen Europe life sciences investment</title>
      <description>
        <![CDATA[Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728861</guid>
      <pubDate>Fri, 13 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728861-vcs-launch-coalition-to-strengthen-europe-life-sciences-investment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.webp?t=1729025266" type="image/jpeg" medium="image" fileSize="220776">
        <media:title type="plain">Gold Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Trade groups call for EU action on third-party litigation funding</title>
      <description>
        <![CDATA[Third-party litigation funding in Europe has created enough of a stir that several trade associations issued a joint statement making the case that the unregulated nature of these funding agreements is increasing the cost of doing business in a region that is already quite expensive.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728261</guid>
      <pubDate>Wed, 28 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728261-trade-groups-call-for-eu-action-on-third-party-litigation-funding</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/EU-flag-vector.webp?t=1764623220" type="image/jpeg" medium="image" fileSize="108718">
        <media:title type="plain">EU flag vector</media:title>
      </media:content>
    </item>
    <item>
      <title>Advamed says LDT legislation still alive on the Hill</title>
      <description>
        <![CDATA[The U.S. FDA’s final rule for regulation of lab-developed tests is now a part of regulatory litigation history, but Scott Whitaker, CEO and president of the Advanced Medical Technology Association, said that while Congress is still considering LDT legislation, any new legislation may differ substantially from previous bills.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728064</guid>
      <pubDate>Wed, 21 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728064-advamed-says-ldt-legislation-still-alive-on-the-hill</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/regulatory-washington-capital.webp?t=1588689711" type="image/png" medium="image" fileSize="560021">
        <media:title type="plain">U.S. Capitol building, Washington D.C.</media:title>
      </media:content>
    </item>
    <item>
      <title>China slashes tariffs on some medical devices</title>
      <description>
        <![CDATA[Beginning Jan. 1, 2026, China will apply provisional import tariff rates lower than the most-favored-nation rates on 935 items, the State Council announced. The move aims to boost collaboration between domestic and international sectors, and to leverage resources of both to expand the supply of high-quality goods.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727603</guid>
      <pubDate>Fri, 09 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727603-china-slashes-tariffs-on-some-medical-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Globe-and-China-flag.webp?t=1766436912" type="image/jpeg" medium="image" fileSize="571448">
        <media:title type="plain">Globe and China flag</media:title>
      </media:content>
    </item>
    <item>
      <title>US, South Korea trade deal eases industry’s pharma tariff fears</title>
      <description>
        <![CDATA[The Korea Biotechnology Industry Organization on Oct. 30 welcomed the bilateral trade deal between the U.S. and South Korea announced during U.S. President Donald Trump’s state visit alongside the Asia-Pacific Economic Cooperation forum in Gyeongju, South Korea.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725690</guid>
      <pubDate>Thu, 30 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725690-us-south-korea-trade-deal-eases-industrys-pharma-tariff-fears</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Donald-Trump-and-Lee-Jae-myung-10-30.webp?t=1761848731" type="image/jpeg" medium="image" fileSize="595818">
        <media:title type="plain">U.S. President Donald J. Trump (left) and South Korea President Lee Jae-myung at the ROK-U.S. summit</media:title>
        <media:description type="plain">U.S. President Donald J. Trump (left) and South Korea President Lee Jae-myung at the ROK-U.S. summit in Gyeongju-si, South Korea Oct. 29. Source: Office of the President Republic of Korea</media:description>
      </media:content>
    </item>
    <item>
      <title>Trump hits drug imports with 100% tariffs, starting Oct. 1</title>
      <description>
        <![CDATA[The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% import duty will apply beginning Oct. 1. However, the flurry of recent announcements by pharma companies of investments in U.S. manufacturing plants may have paid off, with the president saying in his announcement on Truth Social that the 100% rate will be enforced “unless a company is building their manufacturing plant in America.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/724742</guid>
      <pubDate>Tue, 30 Sep 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724742-trump-hits-drug-imports-with-100-tariffs-starting-oct-1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/100-percentage-illustration.webp?t=1758909807" type="image/jpeg" medium="image" fileSize="367958">
        <media:title type="plain">100 percentage illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Trump hits drug imports with 100% tariffs, starting Oct. 1</title>
      <description>
        <![CDATA[The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% import duty will apply beginning Oct. 1. However, the flurry of recent announcements by pharma companies of investments in U.S. manufacturing plants may have paid off, with the president saying in his announcement on Truth Social that the 100% rate will be enforced “unless a company is building their manufacturing plant in America.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/724670</guid>
      <pubDate>Fri, 26 Sep 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724670-trump-hits-drug-imports-with-100-tariffs-starting-oct-1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/100-percentage-illustration.webp?t=1758909807" type="image/jpeg" medium="image" fileSize="367958">
        <media:title type="plain">100 percentage illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>US expands tariff investigations into med tech, robotics, diagnostics</title>
      <description>
        <![CDATA[The Trump administration has launched an investigation into the national security effects of imports of medical equipment, devices, consumables and equipment, laying the groundwork for a potential increase in tariffs targeting the industry. A separate investigation into robotics and industrial machinery began the same day. Med-tech stocks dropped significantly in response to the news as investors fear increased tariffs on the sector. In April, the administration initiated a similar review of the pharmaceutical industry and in August threatened 200% tariffs on that sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724243</guid>
      <pubDate>Thu, 25 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724243-us-expands-tariff-investigations-into-med-tech-robotics-diagnostics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Europe-US-Tariffs-Trade-Map.webp?t=1755812059" type="image/jpeg" medium="image" fileSize="893216">
        <media:title type="plain">Wooden blocks spelling TARIFFS with a U.S. flag on top, placed on a map of Europe</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea pharma group to support exports, Korea-Japan-China trade</title>
      <description>
        <![CDATA[The Korea Pharmaceutical Traders Association said Aug. 26 that it signed a strategic agreement with Korea Trade Insurance Corp. to support South Korean companies exporting biopharmaceutical materials overseas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723866</guid>
      <pubDate>Tue, 02 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723866-korea-pharma-group-to-support-exports-korea-japan-china-trade</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-trade-KTPA-K-Sure-8-29.webp?t=1756492732" type="image/jpeg" medium="image" fileSize="383461">
        <media:title type="plain">K-Sure Chairman and President Jang Young-jin Ryu (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing</media:title>
        <media:description type="plain">K-Sure Chairman and President Jang Young-jin (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing at K-Sure headquarters in Seoul, South Korea Aug. 26.</media:description>
      </media:content>
    </item>
    <item>
      <title>Korea pharma group to support exports, Korea-Japan-China trade</title>
      <description>
        <![CDATA[The Korea Pharmaceutical Traders Association said Aug. 26 that it signed a strategic agreement with Korea Trade Insurance Corp. to support South Korean companies exporting biopharmaceutical materials overseas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723648</guid>
      <pubDate>Fri, 29 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723648-korea-pharma-group-to-support-exports-korea-japan-china-trade</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-trade-KTPA-K-Sure-8-29.webp?t=1756492732" type="image/jpeg" medium="image" fileSize="383461">
        <media:title type="plain">K-Sure Chairman and President Jang Young-jin Ryu (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing</media:title>
        <media:description type="plain">K-Sure Chairman and President Jang Young-jin (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing at K-Sure headquarters in Seoul, South Korea Aug. 26.</media:description>
      </media:content>
    </item>
    <item>
      <title>South Korea hits record $23B pharma production; 2024 exports up 28% </title>
      <description>
        <![CDATA[South Korea’s pharmaceutical manufacturing reached an all-time high of ₩32.86 trillion (US$23 billion) in 2024, representing a 7.3% increase from 2023 and the highest on record since the country began count in 1998.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722712</guid>
      <pubDate>Tue, 29 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722712-south-korea-hits-record-23b-pharma-production-2024-exports-up-28</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-manufacturing.webp?t=1588350006" type="image/png" medium="image" fileSize="429133">
        <media:title type="plain">Tablets on conveyor belt</media:title>
      </media:content>
    </item>
    <item>
      <title>South Korea hits record $23B pharma production; 2024 exports up 28% </title>
      <description>
        <![CDATA[South Korea’s pharmaceutical manufacturing reached an all-time high of ₩32.86 trillion (US$23 billion) in 2024, representing a 7.3% increase from 2023 and the highest on record since the country began count in 1998.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722424</guid>
      <pubDate>Thu, 24 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722424-south-korea-hits-record-23b-pharma-production-2024-exports-up-28</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-manufacturing.webp?t=1588350006" type="image/png" medium="image" fileSize="429133">
        <media:title type="plain">Tablets on conveyor belt</media:title>
      </media:content>
    </item>
    <item>
      <title>Rx tariffs a few weeks away?</title>
      <description>
        <![CDATA[“Pharmaceuticals will be tariffed, probably at the end of the month,” U.S. President Donald Trump said, as he provided a few more details about his proposed global biopharma sector tariff. “We’re going to start off with a low tariff and give the pharmaceutical companies a year or so to build. And then we’re going to make it a very high tariff.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/722163</guid>
      <pubDate>Wed, 16 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722163-rx-tariffs-a-few-weeks-away</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Prescription-drug-bottles-and-pills.webp?t=1623264455" type="image/png" medium="image" fileSize="297425">
        <media:title type="plain">Prescription drug bottles and pills</media:title>
      </media:content>
    </item>
    <item>
      <title>Optimism prevails despite talk of 200% biopharma tariff</title>
      <description>
        <![CDATA[The U.S. Commerce Department isn't expected to complete its Section 232 investigation to build a national security case for imposing tariffs on biopharmaceuticals until the end of the month, but that didn’t stop President Donald Trump from once again teasing a “very, very high” tariff for medicines and their ingredients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721924</guid>
      <pubDate>Wed, 09 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721924-optimism-prevails-despite-talk-of-200-biopharma-tariff</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Pills-bottle-on-100-bills.webp?t=1744839445" type="image/jpeg" medium="image" fileSize="176555">
        <media:title type="plain">Pills, bottle on $100 bills</media:title>
      </media:content>
    </item>
    <item>
      <title>ABPI: UK’s rebate rates ‘send a terrible message’ to global investors</title>
      <description>
        <![CDATA[The U.K. government has doubled the rate that pharmaceutical companies must repay on sales of branded drugs, under the statutory rebate scheme, to a record 31.3%. Only 1-2% of total sales of branded drugs fall under the statutory scheme, but the increase is seen as a sign that an ongoing review of the voluntary scheme is not going well.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721017</guid>
      <pubDate>Wed, 11 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721017-abpi-uks-rebate-rates-send-a-terrible-message-to-global-investors</link>
    </item>
    <item>
      <title>European Commission clamps down on Chinese med tech</title>
      <description>
        <![CDATA[The trade wars spanning the globe lined up some unlikely-seeming adversaries, and such is the case in the trade scrum between the EU and China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720761</guid>
      <pubDate>Tue, 10 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720761-european-commission-clamps-down-on-chinese-med-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-export-trade.webp?t=1591828115" type="image/png" medium="image" fileSize="1264029">
        <media:title type="plain">Shipping container with flag of China</media:title>
      </media:content>
    </item>
  </channel>
</rss>
